anjeso Drug Patent Profile
✉ Email this page to a colleague
When do Anjeso patents expire, and what generic alternatives are available?
Anjeso is a drug marketed by Baudax and is included in one NDA. There are seven patents protecting this drug.
This drug has forty-seven patent family members in thirteen countries.
The generic ingredient in ANJESO is meloxicam. There are twenty-two drug master file entries for this compound. Forty-seven suppliers are listed for this compound. Additional details are available on the meloxicam profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Anjeso
A generic version of anjeso was approved as meloxicam by AVONDALE PHARMS on June 1st, 2004.
Summary for anjeso
International Patents: | 47 |
US Patents: | 7 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 145 |
Patent Applications: | 3,684 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for anjeso |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for anjeso |
What excipients (inactive ingredients) are in anjeso? | anjeso excipients list |
DailyMed Link: | anjeso at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for anjeso
US Patents and Regulatory Information for anjeso
anjeso is protected by seven US patents.
Patents protecting anjeso
Nanoparticulate meloxicam formulations
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: MANAGEMENT OF MODERATE-TO-SEVERE PAIN BY INTRAVENOUS INJECTION
Nanoparticulate meloxicam formulations
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: MANAGEMENT OF MODERATE-TO-SEVERE PAIN BY INTRAVENOUS INJECTION
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: MANAGEMENT OF MODERATE-TO-SEVERE PAIN BY INTRAVENOUS INJECTION
Method of treating pain in elderly patients with mild renal impairment
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: MANAGEMENT OF MODERATE-TO-SEVERE PAIN BY INTRAVENOUS INJECTION IN PATIENTS WITH MILD RENAL IMPAIRMENT
Reduction of flake-like aggregation in nanoparticulate active agent compositions
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: MANAGEMENT OF MODERATE-TO-SEVERE PAIN BY INJECTION
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: MANAGEMENT OF MODERATE-TO-SEVERE PAIN BY INJECTION
Reduction of flake-like aggregation in nanoparticulate active agent compositions
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Baudax | ANJESO | meloxicam | SOLUTION;INTRAVENOUS | 210583-001 | Feb 20, 2020 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Baudax | ANJESO | meloxicam | SOLUTION;INTRAVENOUS | 210583-001 | Feb 20, 2020 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Baudax | ANJESO | meloxicam | SOLUTION;INTRAVENOUS | 210583-001 | Feb 20, 2020 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for anjeso
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Baudax | ANJESO | meloxicam | SOLUTION;INTRAVENOUS | 210583-001 | Feb 20, 2020 | ⤷ Try a Trial | ⤷ Try a Trial |
Baudax | ANJESO | meloxicam | SOLUTION;INTRAVENOUS | 210583-001 | Feb 20, 2020 | ⤷ Try a Trial | ⤷ Try a Trial |
Baudax | ANJESO | meloxicam | SOLUTION;INTRAVENOUS | 210583-001 | Feb 20, 2020 | ⤷ Try a Trial | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
EU/EMA Drug Approvals for anjeso
Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
---|---|---|---|---|---|---|---|---|---|
Norbrook Laboratories (Ireland) Limited | Loxicom | meloxicam | EMEA/V/C/000141 DogsAlleviation of inflammation and pain in both acute and chronic musculoskeletal disorders. To reduce postoperative pain and inflammation following orthopaedic and soft-tissue surgery.CatsAlleviation of inflammation and pain in chronic musculoskeletal disorders in cats. To reduce postoperative pain after ovariohysterectomy and minor soft-tissue surgery.CattleFor use in acute respiratory infection with appropriate antibiotic therapy to reduce clinical signs in cattle. For use in diarrhoea in combination with oral rehydration therapy to reduce clinical signs in calves of over one week of age and young, non-lactating cattle. For adjunctive therapy in the treatment of acute mastitis, in combination with antibiotic therapy.PigsFor use in noninfectious locomotor disorders to reduce the symptoms of lameness and inflammation. For adjunctive therapy in the treatment of puerperal septicaemia and toxaemia (mastitis-metritis-agalactia syndrome) with appropriate antibiotic therapy.HorsesFor use in the alleviation of inflammation and relief of pain in both acute and chronic musculoskeletal disorders.For the relief of pain associated with equine colic. |
Authorised | yes | no | no | 2009-02-10 | |
Le Vet Beheer B.V. | Novaquin | meloxicam | EMEA/V/C/003866 Alleviation of inflammation and relief of pain in both acute and chronic musculo-skeletal disorders in horses. |
Authorised | no | no | no | 2015-09-08 | |
Le Vet Beheer B.V | Meloxidolor | meloxicam | EMEA/V/C/002590 DogsAlleviation of inflammation and pain in both acute and chronic musculoskeletal disorders.Reduction of postoperative pain and inflammation following orthopaedic and soft-tissue surgery.CatsReduction of postoperative pain after ovariohysterectomy and minor soft-tissue surgery.CattleFor use in acute respiratory infection with appropriate antibiotic therapy to reduce clinical signs.For use in diarrhoea in combination with oral rehydration therapy to reduce clinical signs in calves of over one week of age and young, non-lactating cattle.For adjunctive therapy in the treatment of acute mastitis, in combination with antibiotic therapy.PigsFor use in noninfectious locomotor disorders to reduce the symptoms of lameness and inflammation.For the relief of postoperative pain associated with minor soft-tissue surgery such as castration.For adjunctive therapy in the treatment of puerperal septicaemia and toxaemia (mastitis-metritis-agalactia syndrome) with appropriate antibiotic therapy.HorsesFor use in the alleviation of inflammation and relief of pain in both acute and chronic musculoskeletal disorders.For the relief of pain associated with equine colic. |
Authorised | yes | no | no | 2013-04-22 | |
>Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
International Patents for anjeso
See the table below for patents covering anjeso around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
European Patent Office | 3090731 | FORMULES À MÉLOXICANE NANOPARTICULAIRE (FORMULATIONS COMPRISING NANOPARTICULATE MELOXICAM) | ⤷ Try a Trial |
Taiwan | I558422 | ⤷ Try a Trial | |
Canada | 2763456 | REDUCTION DE L'AGREGATION A L'ORIGINE DE PAILLETTES DANS DES COMPOSITIONS A BASE D'UN PRINCIPE ACTIF NANOPARTICULAIRE (REDUCTION OF FLAKE-LIKE AGGREGATION IN NANOPARTICULATE ACTIVE AGENT COMPOSITIONS) | ⤷ Try a Trial |
>Country | >Patent Number | >Title | >Estimated Expiration |